Description:
This is an open label, non-randomised, multicentre Phase I to determine the safety of
tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their
expansion/persistence with control EBV CTL in solid organ transplant patients with
post-transplant lymphoproliferative disease (PTLD). Each patient will receive an infusion of
two ATIMPs - autologous EBV CTL retrovirally transduced with (a) a calcineurin mutant (CNA12)
that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8).
Title
- Brief Title: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
- Official Title: Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant
Clinical Trial IDs
- ORG STUDY ID:
UCL/16/0529
- NCT ID:
NCT03131934
Conditions
- Post-transplant Lymphoproliferative Disease
- Transplant-Related Hematologic Malignancy
Interventions
Drug | Synonyms | Arms |
---|
Autologous EBV-CTL transduced with vector SFG-CNA12 | | Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8 |
Autologous EBV-CTL transduced with control vector SFG-CNA8 | | Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8 |
Purpose
This is an open label, non-randomised, multicentre Phase I to determine the safety of
tacrolimus-resistant autologous EBV-specific cytotoxic T-cells (EBV CTL) and compare their
expansion/persistence with control EBV CTL in solid organ transplant patients with
post-transplant lymphoproliferative disease (PTLD). Each patient will receive an infusion of
two ATIMPs - autologous EBV CTL retrovirally transduced with (a) a calcineurin mutant (CNA12)
that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8).
Detailed Description
This is a multi-centre, non-randomised, open label Phase 1 clinical trial of Advanced Therapy
Investigational Medicinal Products (ATIMPs) in adult and paediatric (age 1-70 years) solid
organ transplant recipients with histologically proven B-lineage EBV+ post-transplant
lymphoproliferative disease (PTLD).
The ATIMPs for this study are autologous EBV CTL transduced with the (a) the retroviral
vector SFG-CNA12 encoding a calcineurin A mutant (CNA12) that confers resistance to
tacrolimus and (b) the retroviral vector SFG-CNA8 encoding a control calcineurin A mutant
(CNA8).
Following informed consent and registration to the trial, patients will undergo an
unstimulated leucapheresis for generation of both ATIMPs. Patients will receive an equal dose
of each ATIMP (10x7 CNA8+ or CNA12+ CTL/m2) which will be administered intravenously.
Other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at
therapeutic levels.The trial will evaluate the safety of the ATIMPs in organ transplant
recipients developing EBV+ PTLD and compare the persistence and frequency of circulating
CNA12 and CNA8 CTL in the peripheral blood.
Our hypothesis is that in the presence of ongoing immunosuppression with tacrolimus, CNA12
CTL will show preferential expansion and prolonged persistence compared with CNA8 CTL. If
successful this will result in durable clearance of PTLD without the need to reduce
tacrolimus, thus reducing the risk of graft rejection.
Patients will be followed up regularly during the interventional phase of the study until 1
year post EBV CTL infusion. During the long-term follow-up phase of the study (from 1-5 years
post EBV CTL infusion) patients will be followed up annually.
Trial Arms
Name | Type | Description | Interventions |
---|
Autologous EBV-CTL transduced with SFG-CNA12/SFG-CNA8 | Experimental | All patients will receive the autologous EBV CTL retrovirally transduced with with (a) a calcineurin mutant (CNA12) that confers resistance to tacrolimus and (b) a control calcineurin mutant (CNA8). For each patient two ATIMPs will be generated:
Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12
Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
An equal dose (10x7/m2) of CNA12+ EBV CTL and CNA8+ EBV CTL will be administered intravenously on day 0.
While awaiting ATIMP generation, patients may receive a single dose of Rituximab and other immunosuppressants (e.g. MMF) will be reduced, but tacrolimus will be maintained at therapeutic levels. | - Autologous EBV-CTL transduced with vector SFG-CNA12
- Autologous EBV-CTL transduced with control vector SFG-CNA8
|
Eligibility Criteria
Inclusion Criteria:
1. Adult and paediatric (age 1-70 years) solid organ transplant recipients with
histologically proven B-lineage EBV+ post-transplant lymphoproliferative disease
(PTLD) either de novo or resistant to Rituximab
2. EBV viraemia at enrolment
3. On immunosuppression with tacrolimus
4. Agreement to have a pregnancy test and use of contraception for duration of trial (if
applicable)
5. Written informed consent
Exclusion Criteria:
1. Fulminant disease
2. Requirement for supplemental oxygen
3. Burkitt's lymphoma/Mature B-acute lymphoblastic leukaemia with IgH-Myc rearrangement
4. T-lineage PTLD
5. Bilirubin > 3 x upper limit of normal
6. Creatinine > 3 x upper limit of normal
7. Active hepatitis B, C or HIV infection
8. Women who are pregnant or breast-feeding
9. ECOG performance score ≥ 4
10. Inability to tolerate leucapheresis
Maximum Eligible Age: | 70 Years |
Minimum Eligible Age: | 1 Year |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Toxicity at 6 weeks post infusion |
Time Frame: | 6 weeks |
Safety Issue: | |
Description: | Toxicity as assessed by NCI Common toxicity criteria within 6 weeks of infusion |
Secondary Outcome Measures
Measure: | Disease response |
Time Frame: | 6 weeks |
Safety Issue: | |
Description: | Disease response at 6 weeks |
Measure: | Relapse rate |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Relapse rate at 1 and 2 years |
Measure: | Disease free survival |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Disease free survival at 1 and 2 yrs |
Measure: | Organ graft Rejection |
Time Frame: | 2 years |
Safety Issue: | |
Description: | Organ graft Rejection at 1 and 2 yrs |
Details
Phase: | Early Phase 1 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | University College, London |
Last Updated
March 31, 2020